UPDATE: B. Riley FBR Maintains Buy On Spectrum, Lowers Target To $11 Notes 'Pozi Ph. II Lung Cancer Update Underwhelming; Not Dead Though as the Sell-Off Might Suggest'

Benzinga · 12/27/2019 13:46